Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolization (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether transarterial chemoembolization with doxorubicin is more effective when given alone or when given together with everolimus in treating patients with liver cancer.

PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of everolimus when given together with transarterial chemoembolization with doxorubicin and to see how well it works compared with giving transarterial chemoembolization with doxorubicin alone in treating patients with liver cancer.

Study Overview

Status

Terminated

Conditions

Detailed Description

OBJECTIVES:

  • Determine the recommended dose of everolimus in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization with doxorubicin-eluting beads (TACE). (Phase I)
  • Determine the efficacy and tolerability of everolimus in patients with HCC treated with TACE as compared to TACE alone. (Phase II)

OUTLINE: This is a multicenter, dose-escalation phase I study followed by a randomized phase II study.

  • Phase I: Patients receive oral everolimus once daily in the absence of disease progression or unacceptable toxicity. Beginning 7 days after the start of everolimus patients undergo transarterial chemoembolization (TACE) comprising doxorubicin-eluting beads into the hepatic artery followed in 4 weeks by an MRI. If viable tumor is found patients undergo another TACE treatment continuing every 4 weeks for up to 5 treatments.
  • Phase II: Patients are stratified according to center, age (≤ 60 vs > 60 years), and number of lesions (≤ 3 vs > 3). Patients are randomized to 1 of 2 treatment arms.

    • Arm I: Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the maximum tolerated dose (MTD).
    • Arm II: Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.

In both arms, patients receive treatment for up to 12 months in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for analysis of AFP tumor markers. Patients also complete quality of life questionnaires, Health Economic Assessment, and EQ5D questionnaires at baseline and periodically during the study.

After completion of study treatment, patients are followed on day 30, and then every 3 months.

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bern, Switzerland, CH-3010
        • Inselspital Bern
      • Chur, Switzerland, 7000
        • Kantonsspital Graubuenden
      • Geneva, Switzerland, CH-1211
        • Hôpital Cantonal Universitaire de Genève
      • Lausanne, Switzerland, CH-1011
        • Centre Hospitalier Universitaire Vaudois
      • Lugano, Switzerland, 6903
        • Clinica Luganese di Moncucco
      • Sion, Switzerland, CH-1951
        • Institut Central des Hopitaux Valaisans / Hôpital de Sion
      • St. Gallen, Switzerland, CH-9007
        • Kantonsspital - St. Gallen
      • Zurich, Switzerland, CH-8091
        • Universitaetsspital Zuerich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically, cytologically, or radiologically confirmed hepatocellular carcinoma

    • Intermediate stage B (according to Barcelona Clinic Liver Cancer classification)
    • Child-Pugh score < 8
    • No tumor involvement > 50% of whole liver
  • No advanced stage disease (i.e., either portal invasion [segmental portal obstruction] or extrahepatic spread)
  • No presence or history of metastatic disease
  • Candidate for transarterial chemoembolization after multidisciplinary discussion (tumor board)
  • Not on an active waiting list for liver transplantation

PATIENT CHARACTERISTICS:

  • WHO performance status 0-1
  • Hemoglobin ≥ 90 g/L
  • Absolute neutrophil count ≥ 1.5 x 10^9/L
  • Platelet count ≥ 100 x 10^9/L
  • Bilirubin ≤ 1.5 x upper limit of normal (ULN)
  • ALT ≤ 4 x ULN
  • INR ≤ 2
  • Creatinine ≤ 1.5 x ULN
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for 12 months after completion of study therapy
  • Negative pregnancy test
  • None of the following contraindications:

    • Complete portal vein thrombosis
    • Large arterio-portal or arterio-venous fistula within the liver
    • Allergy to contrast media
    • Contraindication to hepatic artery catheterization, such as severe peripheral vascular disease precluding catheterization
  • No active heart disease, including any of the following:

    • NYHA class II-IV congestive heart failure
    • Active coronary artery disease (myocardial infarction > 6 months prior to trial entry allowed)
    • Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin permitted)
    • Uncontrolled hypertension
  • No hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg despite optimal medical management
  • No thrombotic or embolic events within the past 6 months including any of the following:

    • Cerebrovascular accident (including transient ischemic attacks)
    • Pulmonary embolism
    • Deep vein thrombosis
  • No serious non-healing wounds, including wounds healing by secondary intention, acute or non-healing ulcers, or bone fractures within 3 months of fracture
  • No evidence of bleeding diathesis
  • No history of hemoptysis
  • No clinically serious infection > grade 2 (NCI CTCAE Version 3.0) except for HBV and HCV infection
  • No known HIV infection
  • No CTCAE acute adverse events grade > 2 after prior TACE therapy
  • No other prior or concurrent malignancy that is distinct in primary site or histology from HCC, except carcinoma in situ of the cervix, treated nonmelanoma skin cancer, superficial bladder tumor (Ta, Tis, T1), or any cancer curatively treated > 3 years prior to entry
  • No psychiatric disorder precluding understanding of information on trial related topics, giving informed consent, filling out QL forms, or interfering with compliance for oral drug intake
  • No serious underlying medical condition, at the judgment of the investigator, which could impair the ability of the patient to participate in the trial (e.g., active autoimmune disease, uncontrolled diabetes)
  • No known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs
  • No contraindication to have MRI (e.g., pacemaker)
  • No organ allograft
  • No known impairment of swallowing that would preclude administration of everolimus
  • Completed baseline quality of life, BL-HEA, and EQ5D questionnaires (Phase II only)
  • Able to comply and have geographic proximity to allow proper staging and follow-up

PRIOR CONCURRENT THERAPY:

  • At least 4 weeks since prior transarterial embolization/chemoembolization [limited to 5 treatments], radiofrequency ablation, cryoablation, radiation therapy or percutaneous ethanol injection
  • At least 4 weeks since prior sorafenib
  • At least 30 days since treatment with other experimental drugs or other anticancer therapy, or treatment in another clinical trial
  • At least 30 days since use of biologic response modifiers (e.g., G-CSF and other hematopoietic growth factors)
  • More than 4 weeks since prior and no concurrent major surgery
  • More than 3 weeks since prior and no concurrent radiotherapy
  • Concurrent erythropoietin allowed provided no dose adjustment is undertaken within 1 month prior to the trial or during the trial
  • No concurrent anticancer drugs (e.g., bevacizumab, and any drugs that target VEGF or VEGF receptors)
  • No concurrent investigational drugs
  • No concurrent known strong CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, itraconazole, voriconazole, erythromycin, clarithromycin, diltiazem, verapamil, and protease inhibitors)
  • No concurrent known strong CYP3A4 inducers (e.g., carbamazepine, continuous treatment with dexamethasone [> 2 mg/day for > 7 days], phenobarbital, phenytoin, rifampicin, and St. John's wort)
  • No concurrent grapefruit, grapefruit juice, and products containing bitter oranges
  • No concurrent systemic corticosteroids (e.g., > 1 mg/kg prednisolone) for more than 2 weeks
  • No concurrent angiotensin converting enzyme inhibitors (ACE-I)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm I
Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Other Names:
  • Adriamycin
Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Experimental: Arm II
Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Other Names:
  • Adriamycin
Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Other Names:
  • RAD001

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dose-limiting toxicity (Phase I)
Time Frame: after 6 weeks from registration
Dose limiting toxicity (DLT) (observed within the first TACE period)
after 6 weeks from registration
Time to progression (Phase II)
Time Frame: 12 weeks after randomisation
12 weeks after randomisation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to progression (Phase I)
Time Frame: 12 weeks after registration
12 weeks after registration
Progression-free survival (Phase II)
Time Frame: Time from randomization until event occurs (see description):
  • Relapse or progression assessed according to the modified RECIST criteria
  • Death of any cause
  • Metastasis outside of liver
Time from randomization until event occurs (see description):
Progression-free survival at 12 months (Phase II)
Time Frame: within 12 months after randomisation
within 12 months after randomisation
Tumor response according to adapted RECIST criteria (Phase II)
Time Frame: during treatment
during treatment
Overall survival (Phase II)
Time Frame: Time from randomisation until death from any cause
Time from randomisation until death from any cause
Response duration (Phase II)
Time Frame: See description
From the time when criteria for response (CR or PR) are met, until documentation of relapse or progression thereafter.
See description
Time to treatment failure (Phase II)
Time Frame: See description
Time from registration to any treatment failure including disease progression or premature (within 12 months) discontinuation of treatment for any reason (e.g., disease progression, toxicity, patient preference, initiation of new treatment without documented progression, Initiation of second line of TACE, Initiation of sorafenib therapy or death).
See description

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jean-Francois Dufour, MD, University Hospital Inselspital, Berne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2010

Primary Completion (Actual)

November 1, 2011

Study Completion (Actual)

June 1, 2015

Study Registration Dates

First Submitted

November 6, 2009

First Submitted That Met QC Criteria

November 6, 2009

First Posted (Estimate)

November 9, 2009

Study Record Updates

Last Update Posted (Estimate)

July 7, 2015

Last Update Submitted That Met QC Criteria

July 3, 2015

Last Verified

July 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Cancer

Clinical Trials on doxorubicin-eluting beads

3
Subscribe